July 17, 2020: Stella Sexton is one of the smart citizens who is helping her. “I’m a blood donor, O-negative,” says the 41-year-old asset manager and mother of two in Lancaster County, Pennsylvania. After your time, baby, she gave additional breast milk to the milk banks. When her children’s school is in session, she is also helping there.
His resolve to participate in a clinical trial for a COVID-19 vaccine was predictable. “I just thought, “I have to help, ” he said. He was in his first vaccine trial, called a Phase I trial, to verify his safety.
Today, vaccine developers want thousands more like her to participate in studies that verify how vaccines paint and how they are in much larger groups.
For them, the National Institutes of Health of the National Institutes of Health has presented them with a new network of clinical trials. Called COVID-19 Prevention Trials Network (CoVPN), it merges 4 clinical trial networks across the country.
“We need to recruit millions of other people to this record through September,” says Jim Kublin, MD, CoVPN’s Executive Director of the Operational Program, coordinated through the Fred Hutchinson Cancer Research Center in Seattle.
En attracting millions of others to sign up on coVPN’s online page will make sure researchers get the numbers they want, as some won’t be eligible. Researchers plan to launch five vaccine trials before the end of the year, Kublin said. They want about 30,000 more people each.
As of July 17, more than 3.59 million cases of COVID-19 had been diagnosed in the United States and more than 138,500 people had died.
On the website, volunteers complete a screening log, which lasts about 15 minutes. They are asked for non-public tactile information, demographics about their position of residence, height, weight, race, ethnicity, occupation, major points of exposure to COVID-19 and knowledge about pre-existing conditions, says Kublin.
It’s attracting a great diversity of people, he says, not just young, healthy people. “The trials are not only aimed at assessing the effectiveness of the vaccine, but also its effect on a person’s health,” he says.
Once completed, the survey data is sent to the exam closest to a volunteer’s location. Some volunteers may be contacted very soon, Kublin says, while others may be contacted later or never. The common reasons why volunteers would be disqualified, he says, less than 18 years ago, were a history of allergic reactions to vaccines or a disease that weakens their immune system.
Volunteers will have a detailed discussion with review so they can make an informed resolution about their membership.
Most studies will require volunteers for the study site 10 or more times for 1 or 2 years. Each test comes to injections or intravenous injections. Some volunteers will get a vaccine and others will get a placebo. None of these studies involve exposing volunteers to the virus that causes COVID-19.
Participants get bills for their time and inconveniences. Payments vary depending on the number of visits and where they are, as the cost of living varies by region.
“This is an unprecedented moment in our history, and it forces us all to get involved, especially those who are possibly vulnerable to infections and diseases,” Kublin said. COVID-19 disproportionately affects other people of color and older adults, he says, so it is vital that they are included in the trials. Vaccines have been thoroughly tested to make sure they are safe, he said.
Much bigger tests are knowing how well they work.
Zoe Evans, 49, principal of a high school in Bowdon, Georgia, began thinking about volunteering in March. He then first learned that Emory University in Atlanta, about 60 miles away, was conducting a Phase I vaccine test. “I looked into it, but Emory was every 18 to 55 years old they needed [for this].”
You have now registered on the CoVPN website. “I had a double emotion,” she says. “I sought help moving faster. I need a vaccine to happen. I can help science, but I can also help myself at the same time. It was a bit of both.”
Another thing that she stepped on her decision: her 23-year-old daughter tested positive in late May. She’s recovered, her sense of smell isn’t 100% yet, she says.
For Shelly Groves, a 56-year-old animal keeper from Atlanta, the resolution of participating in a Phase I trial at Emory was simple. “We needed a vaccine and I knew she was healthy.” In the past, he participated in a clinical trial to see if dog owners can transmit an infectious disease such as influenza to their dog, and if the dog becomes a carrier and transmits the disease to the owner. (You haven’t heard the effects yet). It was a smart experience, so she said she felt comfortable joining another.
She won two injections of the Modern Vaccine being tested, the last on May 14. It’s a messenger RNA vaccine. In addition to a slightly sore arm, he says he had short-term joint pain after the two injections, once in the knees, once in the shoulders, but it was not his daily routine. His advice: “Sure. Help your neighbor.”
Stacey Lapp, 51, a senior research specialist at Emory University, also enrolled. She studied the anthrax vaccine and participated in an HIV vaccine trial. “I’m a scientist and I need to see things move forward,” he says. He doesn’t care about the side effects, he says.
Sexton says volunteering has been “a glorious experience.” He praised test managers for putting their physical condition and protection first. “It made me feel confident that there are a lot of wise and confident people running [with vaccines] behind the scenes.” After the first shot, I was a little tired, but I was still working out, she said. It is helping to verify the Inovio vaccine, which is given with a smart device that uses a brief electrical pulse to open small pores of the skin to administer the DNA vaccine. “It doesn’t hurt, but I wouldn’t do it for fun,” she says.
You will get $1,200 in your 52-week stake. Groves will get $705. As Sexton says, it’s not about money. “I would do it for free. Participating in a vaccine test is really stimulating. You feel like you’re taking action and doing anything to help solve the crisis and get global to normal.”
Stella Sexton, 41, asset manager, Lancaster County, Pennsylvania.
Jim Kublin, MD, Executive Director, CoVPN Operating Program, Fred Hutchinson Cancer Research Center, Seattle.
Zoe Evans, 49, principal of high school, Bowdon, GA.
Shelly Groves, 56, animal keeper, Atlanta.
Stacey Lapp, 51, senior specialist, Emory University, Atlanta.
Press release, National Institutes of Health: “The NIH is launching a network of clinical trials for COVID-19 vaccines and other prevention tools.”
COVID Prevention Network website-19.
© 2005-2019 WebTM LLC. All rights are reserved.
WebMD provides medical advice, diagnosis or treatment.
View information